|
Market Closed -
Euronext Bruxelles
19:55:00 02/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 204.30 EUR | +1.49% |
|
-4.71% | -14.38% |
| 09-30 | Merck's experimental skin disease drug succeeds in mid-stage study | RE |
| 09-29 | UCB Presents Data From Innovative Myasthenia Gravis Portfolio At AANEM Annual Meeting And MGFA Scientific Session | CI |
| Market Cap | 38.95B 43.84B 36.36B 33.14B 62.5B 4,215B 63.08B 440B 170B 2,155B 165B 161B 6,915B | P/E 2026 * |
20.4x | P/E 2027 * | 17x |
|---|---|---|---|---|---|
| Enterprise Value | 39.37B 44.31B 36.74B 33.49B 63.16B 4,259B 63.75B 445B 172B 2,177B 166B 163B 6,988B | EV / Sales 2026 * |
4.55x | EV / Sales 2027 * | 3.88x |
| Free-Float |
61.59% | Yield 2026 * |
0.71% | Yield 2027 * | 0.74% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Bruxelles
| UCB | Real-time | |
CBOE
| UCB | Real-time | |
|
Xetra
| UNC | Delayed | |
|
Tradegate
| UNC | Real-time | |
|
Boerse Muenchen
| UNC | Real-time | |
|
OTC Markets
| UCBJF | Delayed | |
|
Börse Stuttgart
| UNC | Delayed | |
|
London S.E.
| 0NZT | Delayed | |
|
Deutsche Boerse AG
| UNC | Delayed | |
|
CBOE
| 0NZT | Real-time | |
|
Wiener Boerse
| UCB | End-of-day quote | |
|
Borsa Italiana
| 4UCB | End-of-day quote |
Last Transcript: UCB
| 1 day | +1.49% | ||
| 1 week | -4.71% | ||
| Current month | -0.39% | ||
| 1 month | -7.43% | ||
| 3 months | -21.27% | ||
| 6 months | -22.76% | ||
| Current year | -14.38% |
| 1 week | 200.2 |  | 217.1 |
| 1 month | 200.2 | | 217.1 |
| Current year | 200.2 | | 289.5 |
| 1 year | 200.2 | | 289.5 |
| 3 years | 65.4 | | 289.5 |
| 5 years | 65.4 | | 289.5 |
| 10 years | 54.84 | | 289.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 01/01/2015 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 60 | 01/07/2020 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/05/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 01/01/2012 | |
| Director/Board Member | 67 | 01/01/2015 | |
| Director/Board Member | 56 | 24/04/2014 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 15/01/26 | Exercice | Executive/Senior Manager | 3,000 | 0.0015% | ||
| 15/01/26 | Exercice | Executive/Senior Manager | 3,000 | 0.0015% | ||
| 15/01/26 | Buy | Director | 500 | 0.0003% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.49% | -4.71% | -18.93% | +161.25% | 43.84B | |
| -0.61% | -3.43% | +36.07% | +117.61% | 1,019B | |
| -1.02% | -5.60% | +35.72% | +64.82% | 617B | |
| +1.11% | -0.58% | +12.36% | +78.27% | 464B | |
| +0.34% | -3.01% | +61.79% | +41.79% | 356B | |
| -0.95% | -4.05% | +20.54% | +40.33% | 333B | |
| -1.46% | -2.89% | +10.57% | +26.54% | 267B | |
| -1.35% | -5.43% | -6.17% | +8.82% | 244B | |
| -1.04% | -2.79% | +35.30% | +54.42% | 218B | |
| -1.87% | -4.10% | +28.44% | +97.54% | 179B | |
| Average | -0.54% | -3.52% | +21.57% | +69.14% | 374.1B | |
| Weighted average by Cap. | -0.57% | -3.34% | +28.51% | +72.21% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.66B 9.75B 8.08B 7.37B 13.89B 937B 14.02B 97.8B 37.9B 479B 36.59B 35.8B 1,537B | 9.61B 10.81B 8.97B 8.17B 15.41B 1,039B 15.56B 109B 42.05B 531B 40.59B 39.71B 1,705B |
| Net income | 1.93B 2.17B 1.8B 1.64B 3.09B 209B 3.12B 21.78B 8.44B 107B 8.15B 7.97B 342B | 2.3B 2.59B 2.14B 1.95B 3.69B 249B 3.72B 25.94B 10.05B 127B 9.71B 9.49B 408B |
| Net Debt | 413M 464M 385M 351M 662M 44.65B 668M 4.66B 1.81B 22.83B 1.74B 1.71B 73.25B | -1.7B -1.91B -1.58B -1.44B -2.72B -183B -2.74B -19.15B -7.42B -93.76B -7.16B -7.01B -301B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/10/26 | €204.30 | +1.49% | 176,155 |
| 01/10/26 | €201.30 | -1.85% | 237,472 |
| 30/09/26 | €205.10 | -0.82% | 302,223 |
| 29/09/26 | €206.80 | -2.68% | 358,447 |
| 28/09/26 | €212.50 | -0.89% | 281,460 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- UCB Stock
Select your edition
All financial news and data tailored to specific country editions
